4.5 Article

Budesonide enhances agonist-induced bronchodilation in human small airways by increasing cAMP production in airway smooth muscle

出版社

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajplung.00393.2019

关键词

asthma; bronchodilation; chronic obstructive pulmonary disease; corticosteroids; smooth muscle shortening

资金

  1. NIH [P01 HL11447, UL1 TR003017, R01 HL111541, R01 GM107094]
  2. AstraZeneca

向作者/读者索取更多资源

The nongenomic mechanisms by which glucocorticoids modulate beta(2) agonist-induced-bronchodilation remain elusive. Our studies aimed to elucidate mechanisms mediating the beneficial effects of glucocorticoids on agonist-induced bronchodilation. Utilizing human precision-cut lung slices (hPCLS), we measured bronchodilation to formoterol, prostaglandin E-2 (PGE(2)), cholera toxin (CTX), or forskolin in the presence and absence of budesonide. Using cultured human airway smooth muscle (HASM), intracellular cAMP was measured in live cells following exposure to formoterol, PGE(2), or forskolin in the presence or absence of budesonide. We showed that simultaneous budesonide administration amplified formoterol-induced bronchodilation and attenuated agonist-induced phosphorylation of myosin light chain, a necessary signaling event mediating force generation. In parallel studies, cAMP levels were augmented by simultaneous exposure of HASM cells to formoterol and budesonide. Budesonide, fluticasone, and prednisone alone rapidly increased cAMP levels, but steroids alone had little effect on bronchodilation in hPCLS. Bronchodilation induced by PGE(2), CTX, or forskolin was also augmented by simultaneous exposure to budesonide in hPCLS. Furthermore, HASM cells expressed membrane-bound glucocorticoid receptors that failed to translocate with glucocorticoid stimulation and that potentially mediated the rapid effects of steroids on beta(2) agonist-induced bronchodilation. Knockdown of glucocorticoid receptor-alpha had little effect on budesonide-induced and steroid-dependent augmentation of formoterol-induced cAMP generation in HASM. Collectively, these studies suggest that glucocorticoids amplify cAMP-dependent bronchodilation by directly increasing cAMP levels. These studies identify a molecular mechanism by which the combination of glucocorticoids and beta(2) agonists may augment bronchodilation in diseases such as asthma or chronic obstructive pulmonary disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据